P

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Paclitaxel albumin (Abraxane®) (1071/150	In combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.	Not recommended	149	Jun/Jul 2015
Paclitaxel (Abraxane®) (968/14)	Metastatic adenocarcinoma of the pancreas	Non-formulary - lack of clinician demand	146 139	Feb 2015 Jun/Jul 2014
Paclitaxel (Abraxane®)	Metastatic breast cancer		96 89	Apr/May 2010 May 2009
Palbociclib 75mg, 100mg, and 125mg hard capsules (Ibrance®) SMC2149	For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	176	Oct 2019
Palbociclib 75mg, 100mg and 125mg hard capsules (Ibrance®) SMC No 1276/17	For treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor;		166	Feb 2018

	- in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.			
Palifermin (Kepivance®)	Oral mucositis in bone marrow transplantation		58	2006
Paliperidone palmitate 175mg, 263mg, 350mg, 525mg prolonged release suspension for injection (Trevicta®) SMC 1181/16	A three-monthly injection, indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	157	Nov 2016
Paliperidone palmitate prolonged-release suspension for injection (Xeplion®) (713/11)	Schizophrenia	HOSPITAL ONLY (General Adult Psychiatry)	112 109	Dec 2011 Sept 2011
Paliperidone prolonged-release tablets (Invega®) (702/11)	Schizophrenia	Not recommended	105 78	Apr/May 2011 Apr 2008
Palonosetron hydrochloride (Aloxi®) (1073/15)	Prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older.	Non formulary - pending specialist decision	150	Jul 2015
Palonosetron (Aloxi®) (838/13)	Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults	HOSPITAL ONLY (Oncology)	125	Mar/Apr 2013
Palonosetron (Aloxi®) (208/05)	Prevention of chemotherapy induced nausea and vomiting	HOSPITAL ONLY (Oncology & Haematology)	116 54	Apr/May 2012 2005
Panitumumab (Vectibix®) (1082/15)	Treatment of adult patients with wild-type RAS metastatic colorectal cancer first-line in combination with FOLFIRI.	Not recommended	150	June 2015

Panitumumab 20mg/ml concentrate for solution for infusion (Vectibix®) (769/12)	Metastatic colorectal carcinoma	Not recommended	115 80	Mar/Apr 2012 June 2008
Panobinostat 10mg, 15mg and 20mg hard capsules (Farydak®) 1122/16	In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent	Available in line with local guidance for prescribing Hospital only Oncology	154	May 2016
Paracetamol IV (Perfalgan®)	Short-term pain and fever in adults		61 47	2004
Paracetamol IV (Perfalgan®)	Short-term pain and fever in children		99 50	Aug/Sept 2010 2005
Parathyroid hormone 25, 50, 75 and 100 micrograms/dose powder and solvent for solution for injection (Natpar®) SMC No 1334/18	As adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.	Not available as not recommended by SMC	168	May 2018
Parathyroid hormone (Preotact®)	Severe osteoporosis	HOSPITAL ONLY	67 Protocol	Mar 2007
Parecoxib (Dynastat®)	Postoperative pain		24	2003
Paricalcitol (Zemplar®)	Secondary hyperparathyroidism		81 60	July 2008 2006
Paricalcitol capsules (Zemplar®)	Secondary hyperparathyroidism		81	July 2008
Pasireotide (as pamoate) 10, 20, 30 and 40mg powder and solvent for suspension for injection (Signifor®) SMC No	Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.	Not available as not recommended for use in NHS Scotland	167	April 2018

1311/18				
Pasireotide (as pamoate) (Signifor®) (1048/15)	For the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.	Non Formulary - pending local agreement	151	Sep/Oct 2015
Pasireotide (Signifor®) (815/12)	Adult patients with Cushing's disease	Not recommended	121	Nov 2012
Patiromer sorbitex calcium 8.4g and 16.8g powder for oral suspension (Veltassa®) SMC2381	Treatment of hyperkalaemia in adults. SMC restriction: patients with hyperkalaemia (defined as a serum potassium of >6.0mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (raasi) therapy to maintain a clinically acceptable serum potassium level (normokalaemia).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	186	Sept 2021
Patiromer (as patiromer sorbitex calcium) 8.4g and 16.8g powder for oral suspension (Veltassa®) SMC2264	For the treatment of hyperkalaemia in adults.	Not available as not recommended for use in NHS Scotland	182	January 2021
Patiromer (as patiromer sorbitex calcium) 8.4g and 16.8g powder for oral suspension (Veltassa®) SMC No 2084	For the treatment of hyperkalaemia in adults.	Not available as not recommended for use in NHS Scotland	170	Sep 2018
Patiromer sorbitex calcium 8.4mg and 16.8mg powder for oral suspension (Veltassa®) SMC 2568	For the reatment of hyperkalaemia in adults. SMC restriction: in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care. Patiromer sorbitex calcium offers an additional treatment choice in the therapeutic class of non-absorbed cation-exchange compounds that act as potassium binders.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Patisiran 2mg/mL concentrate	The treatment of hereditary transthyretin-mediated	Not routinely availabe as	175	Aug 2019

for solution for infusion (Onpattro®) SMC2157	amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.	local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by September 2019.		
Pazopanib (Votrient®) (820/12)	For the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS).	HOSPITAL ONLY (Oncology)	123 122	Jan 2013 Dec 2012
Pazopanib (Votrient®) (676/10)	Advanced renal cell carcinoma (RCC)	Non-formulary - pending protocol	116 104	Apr/May 2012 Mar 2011
Pegaptanib (Macugen®)	Age-related macular degeneration (AMD)		94 60 Protocol	Dec 09/Jan 10 2006
Pegaspargase 750U/mL solution for injection/infusion (Oncaspar®) SMC 1197/16	As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	158	Dec 2016
Pegcetacoplan 1,080mg solution for infusion (Aspaveli®) SMC2451	In the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months. SMC restriction: under the advice of the national PNH service.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	190	August 2022
Pegfilgrastin (Neulasta®)	Cytotoxic-induced neutropenia		32	2003
Peginterferon alfa-2a 135	Treatment of hepatitis B envelope antigen (HBeAg)-positive	Not available as not	167	April 2018

micrograms and 180 mcrograms solution for injection in pre-filled pen/peginterferon alfa-2a 90 micrograms, 135 micrograms and 180 micrograms solution for injection in pre-filled syringe (Pegasys®) SMC No 1312/18	chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.	recommended for use in NHS Scotland		
Peginterferon (Plegridy®) (1018/14)	Relapsing remitting multiple sclerosis	Available in line with local guidance for prescribing	145	Feb 2015
Peginterferon alfa-2a (Pegasys®) (871/13)	Chronic hepatitis C (CHC)	HOSPITAL ONLY (Paediatric Gastroenterology)	128	June/July 2013
Peginterferon alfa-2a (Pegasys®)	Hepatitis C	HOSPITAL ONLY (Gastroenterology specialist list)	92	Aug/Sep 09 2002
Pegunigalsidase alfa concentrate for solution for infusion (Elfabrio®) SMC2665	For controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. SMC restriction: for use in nor	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	198 not yet published	
Pegunigalsidase alfa concentrate for solution for infusion (Elfabrio®) SMC2591	For long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry Disease (deficiency of alpha-galactosidase).	Not available as not recommended for use in NHS Scotland	195	December 2023
Pegvisomant 10mg, 15mg, 20mg, 25mg and 30mg powder and solvent for solution for injection (Somavert®) SMC No 158/05	Treatment of adult patients with acromegaly who have had an inadequate response to surgery and / or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 [insulin-like growth factor 1] concentrations or was not tolerated.	Available in line with National guidance	165 59 50	Jan 2018 2006 2005
Pegylated interferon alfa-2b	In a combination regimen with ribavirin for the treatment of	HOSPITAL ONLY	119	Aug 2012

(ViraferonPeg®)	children 3 years of age and older and adolescents who have chronic hepatitis C	(Paediatrics)		
Pegylated interferon alfa-2b (ViraferonPeg®)	Hepatitis C	HOSPITAL ONLY (Gastroenterology specialist list)	85 82	Dec 2008 Aug/Sept 2008 2002
Pegylated interferon alfa 2a (Pegasys®)	Hepatitis B in adults	HOSPITAL ONLY (Gastroenterology specialist list)	52	2005
Pegylated liposomal doxorubicin (Caelyx®)	Multiple myeloma		91 83	July 2009 Oct 2008
Pegylated liposomal doxorubicin (Caelyx®)	Metastatic breast cancer		35	2004
Pembrolizumab concentrate for solution for infusion (Keytruda®) SMC2688	In combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung carcinoma at high risk of recurrence in adults.	Not available as not recommended for use in NHS Scotland		
Pembrolizumab concentrate for solution for infusion (Keytruda®) SMC2689	As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy. SMC restriction: adults whose tumours express programmed death-ligand 1 (PD-L1) with less than 50% (0 to 49%) tumour proportion score (TPS).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Pembrolizumab concentrate for solution for infusion	Indication under review: in combination with gemcitabine and cisplatin for the first-line treatment of locally advanced	Not recommended for use in NHS Scotland	198 not yet	

(Keytruda®) SMC2683	unresectable or metastatic biliary tract carcinoma in adults.		published	
Pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®) SMC2660	In combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.	Available in line with national guidance	198 not yet published	
Pembrolizumab concentrate for solution for infusion (Keytruda®) SMC2644	in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.	Not recommended for use in NHS Scotland	198 not yet published	
Pembrolizumab concentrate for solution for infusion (Keytruda®) SMC2589	As monotherapy for adults with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer	Available in line with national guidance	Awaiting publication	Feb 2024
Pembrolizumab 25mg/ml concentrate for solution for infusion (Keytruda®) SMC2501	In combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express programmed death ligand 1 (PD-L1) with a combined positive score (CPS)≥1. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule. In a phase III study, the addition of pembrolizumab to chemotherapy with or without bevacizumab was associated	Available in line with national guidance		

	with a significant improvement in progression-free survival and overall survival in patients with persistent, recurrent or metastatic cervical cancer with PD-L1 CPS≥1.			
Pembrolizumab 25mg/ml concentrate for solution for infusion (Keytruda®) SMC2460	In combination with chemotherapy, for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. SMC restriction: for use in combination with paclitaxel or nab-paclitaxel. Treatment with pembrolizumab is subject to a two-year clinical stopping rule. In one randomised, double-blind, phase III study, pembrolizumab plus chemotherapy significantly improved progression free survival and overall survival compared with chemotherapy alone.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Pembrolizumab 25mg/ml concentrate for solution for infusion (Keytruda®) SMC2474	In combination with lenvatinib, for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule. Pembrolizumab in combination with lenvatinib improved progression-free and overall survival compared with chemotherapy in patients with advanced or recurrent endometrial cancer who had disease progression on or after platinum-based chemotherapy.		191	Nov 2022
Pembrolizumab 25mg/ml concentrate for solution for infusion (Keytruda®) SMC2479	As monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or	191	Nov 2022

	In a phase III study, pembrolizumab significantly improved investigator-assessed disease-free survival (DFS) when compared with placebo.	there is a local preference for alternative medicines.		
Pembrolizumab 25mg/ml concentrate for solution for infusion (Keytruda®) SMC2420	In combination with platinum and fluoropyrimidine based chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS≥10. In a phase III study, pembrolizumab in combination with chemotherapy was associated with significantly improved progression-free survival and overall survival compared with chemotherapy alone.	Available in line with national guidance	189	May 2022
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®) SMC2380		Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	188	April 2022
Pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®) SMC2375	Indication under review: as monotherapy for the first-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule. In an open-label, phase III study, pembrolizumab monotherapy was associated with significantly improved progression-free survival compared with investigator's choice of chemotherapy in patients with metastatic MSI-H/dMMR colorectal cancer. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	187	Dec 2021

	lower.			
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC2247	In combination with axitinib, for the first-line treatment of advanced renal cell carcinoma in adults. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule. In an open-label, phase III study, first-line treatment with pembrolizumab plus axitinib significantly improved progression-free and overall survival in adults with advanced renal cell carcinoma compared with a vascular endothelial growth factor (VEGF)-targeting tyrosine-kinase inhibitor (TKI)	Available in line with national guidance	181	November 2020
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC2257	As monotherapy or in combination with platinum and fluorouracil chemotherapy, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express programmed cell death ligand-1 (PD-L1) with a combined positive score (CPS)≥1. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule. Overall survival was longer in patients who received pembrolizumab as monotherapy or in combination with chemotherapy compared with a monoclonal antibody plus chemotherapy in a phase III study in patients with untreated, locally incurable, recurrent or metastatic HNSCC with PD-L1 CPS≥1.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time	181	November 2020
Pembrolizumab (Keytruda®) (1204/17)	The treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) and who have received at least one prior chemotherapy regimen.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by June 2017	160	Apr 2017
Pembrolizumab (Keytruda®)	The treatment of locally advanced or metastatic non-small cell	Available in line with National	160	Apr 2017

(1204/17)	lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) and who have received at least one prior chemotherapy regimen.	Guidance		
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC2143	As monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing chemotherapy	Available in line with local guidance for prescribing.	173	March 2019
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC2207	For use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.		177	Dec 2019
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC2207	In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations.	Available in line with local guidance for prescribing	177	Dec 2019
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC2187	In combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults.	Available in line with local guidance for prescribing	177	Dec 2019
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC2144	As monotherapy for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.	Available in line with local guidance for prescribing.	175	Aug 2019
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for	In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours	Not available as not recommended for use in NHS Scotland	174	May 2019

concentrate for solution for infusion (Keytruda®) SMC2127	have no EGFR or ALK positive mutations.			
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC No 1339/18	As monotherapy, for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 with a combined positive score (CPS)≥10.	Not available as not recommended for use in NHS Scotland	171	Oct 2018
Pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) SMC No 1291/18	As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin. SMC Restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule. In a phase II study, pembrolizumab was associated with a clinically meaningful overall response rate in adults with classical Hodgkin lymphoma who had failed autologous stem cell transplant and brentuximab vedotin, or who were transplant-ineligible and had failed brentuximab vedotin.	Available in line with national guidance	167 168	April 2018 May 2018
Pembrolizumab 50mg powder for concentrate for solution for infusion and 25mg/mL concentrate for solution for infusion (Keytruda®) SMC No. (1239/17)	As monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) with a ≥50% tumour proportion score (TPS) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive tumour mutations. SMC Restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule	Available in line with national guidance	163	Sep 2017
Pembrolizumab (Keytruda®) (treated with ipilimumab)	As monotherapy for the treatment of advanced (unresectable or	Available in line with National Guidance	152 159	Nov/Dec 2015

(1087/15)	metastatic) melanoma in adults. This submission relates to use in adults previously treated with ipilimumab.			Feb 2017
Pembrolizumab (Keytruda®) (untreated with ipilimumab) (1086/15)	As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously untreated with ipilimumab.	Available in line with national guidance	152 157	Nov/Dec 2015 Nov 2016
Pembrolizumab concentrate for solution for infusion (Keytruda®) SMC2526	As monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection.	Available in line with national guidance		
pembrolizumab concentrate for solution for infusion (Keytruda®) SMC2538	In combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer (TNBC) at high risk of recurrence.	Available in line with national guidance	194	September 2023
Pemetrexed (Alimta®) (192/05)	Malignant pleural mesothelioma	HOSPITAL ONLY (Oncology)	108 Protocol 53	Aug 2011 2005
Pemetrexed (Alimta®) (770/12)	Non-small cell lung cancer	HOSPITAL ONLY (Oncology)	144 115 100 95 58	Jan/Feb 2015 Mar/Apr 2012 Oct/Nov 2010 Feb/Mar 2010 2006
Pemetrexed (Alimta®)	Locally advanced or metastatic non-small cell lung cancer		90 86 82	June 2009 Jan 2009 Aug/Sept

			77 66	2008 Mar 2008 Feb 2007
pemigatinib 4.5mg, 9mg, and 13.5mg tablets (Pemazyre®) SMC2399	for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. In a phase II, single-arm study, pemigatinib demonstrated anti-tumour activity in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma with a FGFR2 fusion or rearrangement who have progressed on at least one line of prior systemic therapy.	Available in line with national guidance	188	April 2022
Pentosan polysulfate sodium (Elmiron) Consilient Health SMC2194	For the treatment of bladder pain syndrome characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	178	Feb 2020
Perampanel 0.5mg/mL oral suspension (Fycompa®) SMC2172	For the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. SMC restriction: use as a second-line adjunctive treatment in patients with refractory partial onset epilepsy who are unable to swallow perampanel tablets. Treatment should be initiated only by physicians who have appropriate experience in the treatment of epilepsy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	176	Oct 2019
Perampanel 0.5mg/mL oral suspension (Fycompa®) SMC2218	For the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.	Not available as not recommended for use in NHS Scotland	176	Oct 2019
Perampanel 2mg, 4mg, 6mg, 8mg, 10mg, 12mg film coated tablets (Fycompa®) SMC	Adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.	Not available as not recommended for use in NHS Scotland.	158	Dec 2016

1200/16				
Perampanel (Fycompa®) (819/12)	Adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.	GPs may prescribe under the direction of the Neurology Clinic	123	Jan 2013
Perindopril arginine (Coversyl Arginine®)	Essential hypertension, symptomatic heart failure		80	June 2008
Perindopril arginine/indapamide (Coversyl Arginine Plus®)	Essential hypertension		80	June 2008
Perindopril/indapamide (Coversyl Plus®)	Hypertension		36 31	2003
Pertuzumab and trastuzumab 600mg/600mg and 1,200mg/600mg solution for injection (Phesgo®) SMC2364	Early breast cancer (EBC) In combination with chemotherapy in: • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence • the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence Metastatic breast cancer (MBC) In combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. SMC restriction: Restricted to use in line with previous SMC advice for pertuzumab and trastuzumab (see SMC2284; SMC2120; SMC2119; SMC No. 928/13; SMC No. 278/06).	Available in line with national guidance	186	Sept 2021
Pertuzumab 420mg concentrate solution for	For use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive	Not routinely available as local clinical experts do not	181	November 2020

infusion (Perjeta®) SMC2284	early breast cancer at high risk of recurrence. SMC restriction: for use in patients with lymph node-positive disease The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease-free survival in patients with HER2-positive early breast cancer at high risk of recurrence	wish to add the medicine to the formulary at this time		
Pertuzumab 420mg concentrate for solution for infusion (Perjeta®) SMC2120	In combination with trastuzumab and docetaxel, in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti HER2 therapy or chemotherapy for their metastatic disease. Addition of pertuzumab to current first-line treatment, trastuzumab plus docetaxel, significantly increased progression-free and overall survival for women with HER2-positive metastatic or locally recurrent unresectable breast cancer	Available in line with local guidance for prescribing.	173	March 2019
Pertuzumab 420mg concentrate for solution for infusion (Perjeta®) SMC2119	For use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence	Available in line with local guidance for prescribing.	173	March 2019
Pertuzumab 420mg concentrate for solution for infusion vial (Perjeta®) 1121/16	For use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.	Not available as not recommended for use in NHS Scotland	154 159	May 2016 Feb 2017
Pertuzumab, 30mg/mL concentrate for solution for infusion (Perjeta®) SMC No. (897/13)	For use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease	Not available as not recommended for use in NHS Scotland	143 131 162	Nov/Dec 2014 Oct/Nov 2013 Aug 2017

Pimecrolimus cream (Elidel®)	Atopic dermatitis		47 Protocol 45 43 33 26	2004 2003
Pioglitazone (Actos®)	Type 2 diabetes mellitus on combination with insulin (monotherapy)	GPs may prescribe under the direction of the Diabetes Clinic	109 98 75 72 67 53 43	Sept 2011 Aug/Sept 2010 Dec 2007 Sept 2007 Mar 2007 2005 2004
Pioglitazone/metformin (Competact®)	Type 2 diabetes mellitus		109 98 61	Sept 2011 Aug/Sept 2010 2006
Pirfenidone 267mg capsule (Esbriet®) (835/13)	In adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).	HOSPITAL ONLY	135 Protocol 130 129	Feb/Mar 2014 Sept/Oct 2013 Aug/Sept 2013
Pitolisant (Wakix®) (1229/17)	Treatment of narcolepsy with or without cataplexy in adults	Not available as not recommended for use in NHS Scotland	160	Apr 2017
Pitolisant film-coated tablets (Wakix) Bioprojet UK Limited SMC2662	To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP).	Not available as not recommended for use in NHS Scotland	197	May/June 2024

pixantrone (Pixuvri®) (1138/16)	As monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas.	Not available as not recommended for use in NHS Scotland	154	May 2016
Plerixafor 20mg/mL solution for injection (Mozobil®) SMC 2249	In combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged 1 year to <18 years with lymphoma or solid malignant tumours, either: - pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilisation with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or - who previously failed to collect sufficient haematopoietic stem cells.	Available from a specialist centre in another NHS Board.	179	Apr 2020
Plerixafor (Mozobil®)	In combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly	Non-formulary - pending protocol	116 94	Apr/May 2012 Dec 09/Jan 10
Polatuzumab vedotin powder for concentrate for solution for infusion (Polivy®) SMC2524	in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Polatuzumab vedotin 140mg powder for concentrate for solution for infusion (Polivy®) SMC2282	In combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant. In a phase Ib/II study polatuzumab vedotin in combination with bendamustine and rituximab significantly increased complete response rate compared to bendamustine and rituximab alone	Available in line with local guidance for prescribing	181	November 2020

Polatuzumab vedotin powder for concentrate for solution with infusion (Polivy®) SMC2525	in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). SMC restriction: patients with an International Prognostic Index (IPI) score of 2 to 5	Available in line with national guidance	194	September 2023
Pomalidomide 1mg , 2mg , 3mg and 4mg hard capsules (Imnovid®) SMC2219	As combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant	Not available as not recommended for use in NHS Scotland	176	Oct 2019
Pomalidomide (Imnovid®) (972/14)	Adult patients with relapsed and refractory multiple myeloma	HOSPITAL ONLY (Haematology)	144 140	Jan/Feb 2015 Jul/Aug 2014
Ponatinib (Iclusig®) (1032/15)	Adult patients with: - Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. - Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	Non-Formulary - Absence of clinician demand	147	Apr 2015
ponesimod titration pack and 20mg film-coated tablets (Ponvory®) SMC2384		Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	188	April 2022

Posaconazole (Noxafil®) (1067/15)	For use in the treatment of fungal infections in adults.	Formulary Haematology patients who require oral posaconazole for prophylaxis, but oral route is not available Otherwise needs approved by Infectious Diseases/Microbiology	150	June 2015
Posaconazole (Noxafil®) (999/14)	Fungal infections	Formulary - HOSPITAL ONLY Haematology	142	Oct/Nov 2014
Posaconazole (Noxafil®)	Prophylaxis of invasive fungal infections in immunocompromised patients		73 69	Oct 2007 June 2007
Posaconazole (Noxafil®)	Specific invasive fungal infections		60 59	2006
Potassium citrate and potassium hydrogen carbonate 8mEq and 24mEq prolonged-release granules (Sibnayal®) SMC2409	For the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older. In a phase II/III open-label sequential study, potassium citrate/potassium hydrogen carbonate was non-inferior to standard alkalising agents measured by average blood bicarbonate levels during 3 days of treatment at steady state in patients with dRTA.	ADULTS - not routinely available as local clinical experts to not wish to add the medicine to the formulary at this time of there is a local preference for alternative medicines.	190	August 2022

Pralsetinib 100mg hard capsules (Gavreto®) SMC2496	As monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	193	
Pramipexole (Mirapexin®)	Idiopathic Parkinson's disease		94	Dec 09/Jan 10
Pramipexole (Mirapexin®)	Restless legs syndrome		58	2006
Prasterone 6.5mg pessary (Intrarosa®) SMC 2255	Treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.		178	Feb 2020
Prasugrel (Efient®)	Prevention of atherothrombotic events in patient with acute coronary syndrome	GPs may prescribe under the direction of Cardiology Click here for Angioplasty antiplatelet algorithm	95 92	Feb/Mar 2010 Aug/Sept 2009
Prednisone (Lodotra®) (771/12)	Moderate to severe, active rheumatoid arthritis in adults	Not recommended	115	Mar/Apr 2012
Pregabalin (Lyrica®) (765/12)	Peripheral and central neuropathic pain in adults	Epilepsy/PNP: Non-formulary - absence of clinician demand CNP/GAD: Not recommended	119 118	Aug/Sept 2012 July 2012
Pregabalin (Lyrica®)	Generalised anxiety disorder in adults		64	2006
Pregabalin (Lyrica®)	Adjunctive epilepsy therapy		48	2005
Pregabalin (Lyrica®)	Central neuropathic pain		72	Sept 2007

Pregabalin (Lyrica®)	Peripheral neuropathic pain	Formulary - restricted use	100 92 89 60 53 49	Oct/Nov 2010 Aug/Sept 2009 May 2009 2006 2005
Prilocaine hydrochloride (Priloketal®) (665/10)	Spinal anaesthesia	HOSPITAL ONLY	103 102	Feb/Mar 2011 Jan/Feb 2011
Progesterone vaginal capsules (Utrogestan®) SMC2630	Prevention of preterm birth in women with a singleton pregnancy who have a short cervix (mid-trimester sonographic cervix ≤25 mm) and/or a history of spontaneous preterm birth.	Not available as not recommended for use in NHS Scotland	195	December 2023
Progesterone 25mg solution for injection (Lubion®) SMC2017	In adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations. This increases the range of progesterone preparations available for use in NHS Scotland. Lubion® is an aqueous formulation and may be administered subcutaneously or intramuscularly.	Available in line with national guidance	170	Sep 2018
Progesterone 100mg vaginal tablets (Lutigest®) SMC 1185/16	Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women.	Available in line with national guidance	158	Dec 2016
Propiverine hydrochloride (Detrunorm XL®)	Urinary incontinence		66	Feb 2007
Propofol MCT-LCT (Propofol Lipuro®)	Anaesthesia		35	2004
Prucalopride (Resolor®)	Chronic constipation in women	HOSPITAL ONLY (Pelvic Floor Clinic)	135 Policy 109 101	Feb/Mar 2014 Sept 2011

				Dec 10/Jan 2011

Updated: 16th January 2024

Back to top Back to homepage